Phase I trial of thalidomide and Interleukin-2 in patients with metastatic renal cell carcinoma
暂无分享,去创建一个
T. Olencki | T. Mekhail | R. Bukowski | R. Dreicer | P. Elson | L. Wood | Sareena Malhi
[1] S. Steinberg,et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] E. Maher,et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] C. Bennett,et al. Thalidomide-associated deep vein thrombosis and pulmonary embolism. , 2002, The American journal of medicine.
[4] B. Rini,et al. A high rate of venous thromboembolism in a multi‐institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma , 2002, Cancer.
[5] P. Thall,et al. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma , 2002, Cancer.
[6] B. Escudier,et al. Phase II trial of thalidomide in renal-cell carcinoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] Hannes Kaufmann,et al. Thromboembolic events during treatment with thalidomide. , 2002, Blood.
[8] R. Motzer,et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] B. Barlogie,et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. , 2001, Blood.
[10] S. Steinberg,et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] C. Boshoff,et al. Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer , 2000, British Journal of Cancer.
[12] R. Bukowski. Natural history and therapy of metastatic renal cell carcinoma , 1997, Cancer.
[13] T. Olencki,et al. Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: clinical results and immunologic correlates of response. , 1997, Journal of immunotherapy.
[14] N. Mulder,et al. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Motzer,et al. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Robert W. Colman. Hemostasis and thrombosis: Basic principles and clinical practice , 1987 .
[17] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.